药学社会责任体系管理的现代途径

O. Kozyrieva, O. Posilkina, S. Kovalenko, Yu. A. Bratishko, E. Litvinova
{"title":"药学社会责任体系管理的现代途径","authors":"O. Kozyrieva, O. Posilkina, S. Kovalenko, Yu. A. Bratishko, E. Litvinova","doi":"10.53920/es-2021-2-6","DOIUrl":null,"url":null,"abstract":"Research is devoted to the development of theoretical, methodological and scientific-practical principles of management of socially responsible activities of domestic pharmaceutical companies as a key condition for improving the quality, efficiency and accessibility of pharmaceutical supply, which is especially relevant in a global pandemic, closing state borders and domestic pharmaceutical companies with foreign partners. In addition, the introduction of approaches and tools of socially responsible management in the activities of domestic pharmaceutical companies will increase their investment attractiveness and improve their business reputation, which will have a positive impact on increasing their competitiveness in both domestic and foreign pharmaceutical markets. In the conditions of development of globalization and integration processes, formation of network economy and knowledge society, rapid expansion and complication of interrelations of national economies and people, growth of their interdependence the problem of socially responsible functioning of business, including based on the introduction of international standards of social responsibility (JI). The coronavirus pandemic (COVID-19) has also significantly changed attitudes toward company priorities around the world. The global pharmaceutical industry was one of the first to feel the effects of the closure of China's economy, which accounts for about 40% of world production of active pharmaceutical ingredients (APIs), and other raw material suppliers. The closure of borders and the long-term quarantine regime have posed significant threats not only to the supply chain for pharmaceutical manufacturers, but have also seriously affected the efficiency of pharmacy as a whole. There was a decrease in sales of prescription drugs (drugs), which complicates the withdrawal of new drugs and stimulates changes in the distribution system. The research activities of pharmaceutical companies (FCs) in non-COVID-19 areas have slowed significantly due to the pandemic. Most clinical trials have had to be suspended due to quarantine restrictions, which are slowing the launch of new drugs. Thus, the pandemic disrupted the normal functioning of all components of domestic pharmacy and exacerbated the problem of access to the population of quality pharmaceutical care. The current situation in domestic and international pharmacy should be a major impetus for a complete rethinking of the philosophy of FC, which in these difficult times must finally realize its own great JI, and begin to build more transparent, open, innovative and socially caring. Only the actions of the FC, as socially responsible organizations, will create hope for the survival not only of individual companies, but also of domestic pharmacy as a whole, and, accordingly, to preserve the health of the population of Ukraine.","PeriodicalId":117522,"journal":{"name":"Economic Synergy","volume":"82 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MODERN APPROACHES TO THE MANAGEMENT OF THE SOCIAL RESPONSIBILITY SYSTEM IN PHARMACY\",\"authors\":\"O. Kozyrieva, O. Posilkina, S. Kovalenko, Yu. A. Bratishko, E. Litvinova\",\"doi\":\"10.53920/es-2021-2-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Research is devoted to the development of theoretical, methodological and scientific-practical principles of management of socially responsible activities of domestic pharmaceutical companies as a key condition for improving the quality, efficiency and accessibility of pharmaceutical supply, which is especially relevant in a global pandemic, closing state borders and domestic pharmaceutical companies with foreign partners. In addition, the introduction of approaches and tools of socially responsible management in the activities of domestic pharmaceutical companies will increase their investment attractiveness and improve their business reputation, which will have a positive impact on increasing their competitiveness in both domestic and foreign pharmaceutical markets. In the conditions of development of globalization and integration processes, formation of network economy and knowledge society, rapid expansion and complication of interrelations of national economies and people, growth of their interdependence the problem of socially responsible functioning of business, including based on the introduction of international standards of social responsibility (JI). The coronavirus pandemic (COVID-19) has also significantly changed attitudes toward company priorities around the world. The global pharmaceutical industry was one of the first to feel the effects of the closure of China's economy, which accounts for about 40% of world production of active pharmaceutical ingredients (APIs), and other raw material suppliers. The closure of borders and the long-term quarantine regime have posed significant threats not only to the supply chain for pharmaceutical manufacturers, but have also seriously affected the efficiency of pharmacy as a whole. There was a decrease in sales of prescription drugs (drugs), which complicates the withdrawal of new drugs and stimulates changes in the distribution system. The research activities of pharmaceutical companies (FCs) in non-COVID-19 areas have slowed significantly due to the pandemic. Most clinical trials have had to be suspended due to quarantine restrictions, which are slowing the launch of new drugs. Thus, the pandemic disrupted the normal functioning of all components of domestic pharmacy and exacerbated the problem of access to the population of quality pharmaceutical care. The current situation in domestic and international pharmacy should be a major impetus for a complete rethinking of the philosophy of FC, which in these difficult times must finally realize its own great JI, and begin to build more transparent, open, innovative and socially caring. Only the actions of the FC, as socially responsible organizations, will create hope for the survival not only of individual companies, but also of domestic pharmacy as a whole, and, accordingly, to preserve the health of the population of Ukraine.\",\"PeriodicalId\":117522,\"journal\":{\"name\":\"Economic Synergy\",\"volume\":\"82 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Economic Synergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53920/es-2021-2-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Economic Synergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53920/es-2021-2-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

研究致力于发展管理国内制药公司社会责任活动的理论、方法和科学实践原则,作为提高药品供应的质量、效率和可及性的关键条件,这在全球大流行病、关闭国家边界和国内制药公司与外国伙伴合作的情况下尤其重要。此外,在国内制药企业的活动中引入社会责任管理的方法和工具,将增加其投资吸引力,提高其商业信誉,这将对提高其在国内外制药市场的竞争力产生积极影响。在全球化和一体化进程发展的条件下,网络经济和知识社会的形成,国家经济和人民之间的相互关系迅速扩大和复杂化,相互依存关系的增长,企业的社会责任职能问题,包括基于社会责任国际标准的引入(JI)。冠状病毒大流行(COVID-19)也显著改变了世界各地对公司优先事项的态度。全球制药业是最先感受到中国经济关闭影响的行业之一,中国占世界原料药(api)和其他原材料供应商产量的40%左右。边境的关闭和长期隔离制度不仅对药品制造商的供应链构成了重大威胁,而且也严重影响了整个制药业的效率。处方药的销售减少了,这使得新药的撤回变得复杂,并刺激了分销系统的变化。受新冠疫情影响,制药企业在非新冠肺炎地区的研究活动大幅放缓。由于隔离限制,大多数临床试验不得不暂停,这减缓了新药的推出。因此,这种流行病扰乱了国内药房所有组成部分的正常运作,加剧了向人口提供高质量药品服务的问题。当前国内外药学的现状应该成为对FC哲学进行全面反思的主要动力,在这个困难时期,FC必须最终实现自己的伟大JI,并开始建立更加透明、开放、创新和社会关怀的理念。只有FC作为对社会负责的组织采取行动,才能不仅为个别公司的生存创造希望,而且为整个国内制药企业的生存创造希望,从而维护乌克兰人民的健康。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
MODERN APPROACHES TO THE MANAGEMENT OF THE SOCIAL RESPONSIBILITY SYSTEM IN PHARMACY
Research is devoted to the development of theoretical, methodological and scientific-practical principles of management of socially responsible activities of domestic pharmaceutical companies as a key condition for improving the quality, efficiency and accessibility of pharmaceutical supply, which is especially relevant in a global pandemic, closing state borders and domestic pharmaceutical companies with foreign partners. In addition, the introduction of approaches and tools of socially responsible management in the activities of domestic pharmaceutical companies will increase their investment attractiveness and improve their business reputation, which will have a positive impact on increasing their competitiveness in both domestic and foreign pharmaceutical markets. In the conditions of development of globalization and integration processes, formation of network economy and knowledge society, rapid expansion and complication of interrelations of national economies and people, growth of their interdependence the problem of socially responsible functioning of business, including based on the introduction of international standards of social responsibility (JI). The coronavirus pandemic (COVID-19) has also significantly changed attitudes toward company priorities around the world. The global pharmaceutical industry was one of the first to feel the effects of the closure of China's economy, which accounts for about 40% of world production of active pharmaceutical ingredients (APIs), and other raw material suppliers. The closure of borders and the long-term quarantine regime have posed significant threats not only to the supply chain for pharmaceutical manufacturers, but have also seriously affected the efficiency of pharmacy as a whole. There was a decrease in sales of prescription drugs (drugs), which complicates the withdrawal of new drugs and stimulates changes in the distribution system. The research activities of pharmaceutical companies (FCs) in non-COVID-19 areas have slowed significantly due to the pandemic. Most clinical trials have had to be suspended due to quarantine restrictions, which are slowing the launch of new drugs. Thus, the pandemic disrupted the normal functioning of all components of domestic pharmacy and exacerbated the problem of access to the population of quality pharmaceutical care. The current situation in domestic and international pharmacy should be a major impetus for a complete rethinking of the philosophy of FC, which in these difficult times must finally realize its own great JI, and begin to build more transparent, open, innovative and socially caring. Only the actions of the FC, as socially responsible organizations, will create hope for the survival not only of individual companies, but also of domestic pharmacy as a whole, and, accordingly, to preserve the health of the population of Ukraine.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信